Find in Library

<strong></strong><p><strong><em>Background:</em></strong><strong> </strong><em>Staphylococcus aureus</em> is a major human pathogen worldwide. Vancomycin has been used for decades to treat multidrug resistant <em>S. aureus</em>. Ten years has passed since the first report of van­comycin resistant <em>S. aureus</em> (VRSA). The objective of this systematic review was to determine the total number of VRSA isolates that have been reported from Iran.</p> <p><strong><em>Methods: </em></strong> Search terms reflected “Iran”, “vancomycin” and “<em>S. aureus</em>” were searched in the ISI web of knowledge, PubMed, SciVerse, and Google scholar. Also two Persian scientific databases and 13 recent national congresses were investigated. Articles / abstracts working on <em>S. aureus</em> in Iran, evaluating vancomycin MIC and/or PCR of <em>vanA/B</em> were included in this systematic review.<strong></strong></p> <p><strong><em>Results:</em></strong> Out of the 3484 records found in mentioned resources, 13 re­lated studies were included in the final analysis. The result showed that at least 24 VRSA isolates which have been reported from Iran up to September 2012.</p> <strong><em>Conclusion:</em></strong> It seems that many Iranian researchers did not follow a specific guideline for reporting and confirming VRSA. Establishing an Iranian reference center where studies on VRSA can be registered, evaluated and confirmed is strongly recommended.<strong> </strong>